Skip to main content
SpringerLink
Log in

CHA2DS2-VASc score predicts 30-day readmission due to thromboembolic complications following cardioversion of atrial fibrillation: insights from US National Readmissions Database

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Purpose

Determine whether the CHA2DS2-VASc score predicts rates of hospitalization associated with thromboembolic complications (TEC) in the 30, 60, and 90 days following cardioversion (CV) for atrial fibrillation (AF).

Methods

The 2014 National Readmissions Database was analyzed to identify readmissions following the index hospitalization for AF and CV. A CHA2DS2-VASc score was calculated for each patient from diagnosis codes associated with the index admission. The primary outcome was the incidence of readmission due to TEC in the 30, 60, and 90 days after CV stratified by CHA2DS2-VASc scores ≤ 1, 2–3, and ≥ 4; the secondary outcome was specific clinical risk factors independently associated with TEC within 30 days of CV.

Results

A total of 109,420 weighted index admissions for AF and CV were identified in between January 1, 2014, and November 30, 2014. Of these, 16,535 (15.1%) had a CHA2DS2-VASc score of 0–1, 39,544 (36.1%) had a score of 2–3, and 53,340 (48.8%) had a score of ≥ 4. Readmission due to TEC occurred in 48 (0.29%), 167 (0.42%), and 394 (0.74%) patients with CHA2DS2-VASc scores ≤ 1, 2–3, and ≥ 4, respectively, in the 90-day period after CV. The only significant predictor for 30-day TEC-associated readmission after CV was age > 65 years old.

Conclusions

This study demonstrated the utility of CHA2DS2-VASc score in predicting TEC-associated readmission rate following CV and the temporal relationship of TEC to CV. Patients > 65 years old without other comorbidities may benefit from 30-day OAC following successful CV irrespective of the duration of AF episodes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Am Med Assoc. 2001;285:2370–5. https://doi.org/10.1001/jama.285.18.2370.

    Article  CAS  Google Scholar 

  2. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts. Circulation. 2017:1. https://doi.org/10.1161/circulationaha.117.028981.

  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–8. https://doi.org/10.1161/01.str.22.8.983.

    Article  CAS  PubMed  Google Scholar 

  4. Lip GYHH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2017;137:263–72. https://doi.org/10.1378/chest.09-1584.

    Article  Google Scholar 

  5. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–104. https://doi.org/10.1161/cir.0000000000000040.

    Article  Google Scholar 

  6. Garg A, Khunger M, Seicean S, Chung MK, Tchou PJ. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. JACC Clin Electrophysiol. 2016;2:487–94. https://doi.org/10.1016/j.jacep.2016.01.018.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Katritsis DG, Josephson ME. Anticoagulation for cardioversion of acute onset atrial fibrillation: time to revise guidelines? JACC Clin Electrophysiol. 2016;2:495–7. https://doi.org/10.1016/j.jacep.2016.03.002.

    Article  PubMed  Google Scholar 

  8. von Besser K, Mills AM. Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation? Ann Emerg Med. 2011;58:517–20. https://doi.org/10.1016/j.annemergmed.2011.06.014.

    Article  Google Scholar 

  9. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–10. https://doi.org/10.1093/eurheartj/ehr488.

    Article  PubMed  Google Scholar 

  10. Airaksinen KEJ, Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62:1187–92. https://doi.org/10.1016/j.jacc.2013.04.089.

    Article  PubMed  Google Scholar 

  11. HCUP Nationwide Readmissions Database (NRD). Healthcare Cost and Utilization Project (HCUP). Agency for healthcare research and quality. MD: Rockville; 2014. www.hcup-us.ahrq.gov/nisoverview.jsp

    Google Scholar 

  12. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Agency for healthcare research and quality. MD: Rockville; 2014. www.hcup-us.ahrq.gov/nisoverview.jsp

    Google Scholar 

  13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70. https://doi.org/10.1001/jama.285.22.2864.

    Article  CAS  PubMed  Google Scholar 

  14. Khan IA. Atrial stunning: basics and clinical considerations. Int J Cardiol. 2003;92:113–28. https://doi.org/10.1016/S0167-5273(03)00107-4.

    Article  PubMed  Google Scholar 

  15. Kleemann T, Becker T, Strauss M, Schneider S, Seidl K. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22:1403–8. https://doi.org/10.1016/j.echo.2009.09.015.

    Article  PubMed  Google Scholar 

  16. Kamel H, Okin PM, Elkind MSV, Iadecola C. Atrial fibrillation and mechanisms of stroke. Time a New Model. 2016;47:895–900. https://doi.org/10.1161/strokeaha.115.012004.

    Article  Google Scholar 

  17. Li-Saw-Hee FL, Blann AD, Gurney D, et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur. Heart J. 2001; doi: https://doi.org/10.1053/euhj.2000.2531

  18. Ziegler PD. The temporal relationship between atrial fibrillation and ischemic stroke. J Atr Fibrillation. 2013. https://doi.org/10.4022/jafib.738.

  19. Rothrock J, Majidi S, Burger K, et al. Inpatient versus outpatient management of TIA or minor stroke: clinical outcome. Neurology. 2016;9:49–53.

    Google Scholar 

  20. Deguchi I, Hayashi T, Ohe Y, Kato Y, Nagoya H, Fukuoka T, et al. The CHA(2)DS(2)-VASc score reflects clinical outcomes in nonvalvular atrial fibrillation patients with an initial cardioembolic stroke. J Stroke Cerebrovasc Dis. 2013;22:e343–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.02.018.

    Article  PubMed  Google Scholar 

  21. D’Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study Stroke. 1994;25:40–3. https://doi.org/10.1161/01.str.25.1.40.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Cardiovascular Disease, The Ohio State University, 395 West 12th Avenue, Suite 334, Columbus, OH, 43210-1267, USA

    Benjamin Buck & Avirup Guha

  2. Department of Internal Medicine, Division of Cardiovascular Disease, Section of Electrophysiology, The Ohio State University, Columbus, OH, USA

    Toshimasa Okabe & Emile Daoud

Authors
  1. Benjamin Buck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshimasa Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Avirup Guha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emile Daoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Buck.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buck, B., Okabe, T., Guha, A. et al. CHA2DS2-VASc score predicts 30-day readmission due to thromboembolic complications following cardioversion of atrial fibrillation: insights from US National Readmissions Database. J Interv Card Electrophysiol 56, 55–61 (2019). https://doi.org/10.1007/s10840-019-00593-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-019-00593-0

Keywords

Search

Navigation